We''re upgrading our rating on AbbVie amid a false report on the biopharma''s guidance
SVB Securities had to issue a clarification after releasing a false report concerning AbbVie''s (ABBV) guidance.
We''re upgrading our rating on AbbVie amid a false report on the biopharma''s guidance
SVB Securities had to issue a clarification after releasing a false report concerning AbbVie''s (ABBV) guidance.